Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMD7X1O)

Drug Name
Dexrazoxane Drug Info
Synonyms
24584-09-6; Zinecard; (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione); Cardioxane; ICRF-187; Dexrazoxano; Dexrazoxanum; Dextrorazoxane; Dexrazoxanum [INN-Latin]; Dexrazoxano [INN-Spanish]; Desrazoxane; Eucardion; ADR 529; ICRF 187; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; Dexrazone; ADR-529; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; HSDB 7319; UNII-048L81261F; NSC169780; dyzoxane; BRN 5759131; CHEBI:50223; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; NSC 169780; AK-72797; Razoxanum; Cardioxane; Dyzoxane; Savene; TopoTect; Totect; Dexrazoxane HCl; Dexrazoxane hydrochloride; ICRF 187 hydrochloride; Cardioxane (TN); Dexrazoxane (TN); Totect (TN); Zinecard (TN); Dexrazoxane (USAN/INN); Dexrazoxane [USAN:BAN:INN]; Soluble ICRF (L-isosomer); Razoxane, (S)-Isomer; Totect, ICRF-187, Zinecard, Cardioxane, Dexrazoxane Hydrochloride;(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; (+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-(9CI); 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride; Icrf-187
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
71384
ChEBI ID
CHEMBL1738
CAS Number
CAS 24584-09-6
TTD Drug ID
D07XVN
VARIDT Drug ID
DR00417
INTEDE Drug ID
DR1772

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Proteasome 2.05 0.00e+0 44/46 (95.65%) PSMD9;PSMD2;PSMD4;...
Spliceosome 1.89 4.40e-2 101/150 (67.33%) HSPA8;CTNNBL1;SRSF4;...
Bacterial invasion of epithelial cells 1.86 4.61e-2 59/77 (76.62%) CLTB;CAV1;CDH1;...
Progesterone-mediated oocyte maturation 1.85 3.46e-2 75/100 (75%) CCNB1;AURKA;PLK1;...
Proteoglycans in cancer 1.80 4.52e-2 172/205 (83.9%) SDC2;CDKN1A;MSN;...
Ascorbate and aldarate metabolism -1.59 4.95e-2 15/30 (50%) UGT2B28;UGDH;ALDH7A1;...
Pentose phosphate pathway -1.59 4.92e-2 25/30 (83.33%) FBP1;ALDOA;DERA;...
Steroid hormone biosynthesis -1.63 3.32e-2 43/61 (70.49%) CYP21A2;STS;SRD5A1;...
Valine, leucine and isoleucine degradation -1.65 2.85e-2 42/48 (87.5%) HADHB;BCKDHA;HMGCL;...
N-Glycan biosynthesis -1.66 2.62e-2 38/50 (76%) MAN1A2;RPN1;DPM3;...
Pyruvate metabolism -1.67 2.54e-2 41/47 (87.23%) FH;ADH1A;ACACB;...
Amino sugar and nucleotide sugar metabolism -1.67 2.60e-2 38/48 (79.17%) UGDH;UAP1;NANS;...
Steroid biosynthesis -1.71 1.91e-2 19/20 (95%) LIPA;CYP27B1;CYP51A1;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis -1.72 1.71e-2 20/26 (76.92%) DPM2;PIGK;PIGT;...
Pentose and glucuronate interconversions -1.77 8.02e-3 17/34 (50%) UGT2B28;UGDH;CRYL1;...
Folate biosynthesis -1.78 7.40e-3 23/26 (88.46%) DHFR;PAH;GGH;...
Nitrogen metabolism -1.78 8.02e-3 16/17 (94.12%) CA12;CA9;GLUL;...
Base excision repair -1.81 4.38e-3 29/33 (87.88%) POLD2;MBD4;APEX2;...
Alanine, aspartate and glutamate metabolism -1.82 3.21e-3 27/37 (72.97%) GAD1;GLS2;AGXT;...
One carbon pool by folate -1.88 8.91e-4 15/20 (75%) ALDH1L1;DHFR;MTHFD2L;...
Metabolism of xenobiotics by cytochrome P450 -1.91 0.00e+0 49/77 (63.64%) UGT2B15;CYP2C9;GSTM3;...
Fanconi anemia pathway -1.92 0.00e+0 36/54 (66.67%) RPA4;REV3L;POLI;...
Glycolysis / Gluconeogenesis -1.96 0.00e+0 56/67 (83.58%) ENO1;TPI1;ADH1B;...
Mismatch repair -1.99 0.00e+0 22/23 (95.65%) LIG1;MLH1;RFC1;...
Glycine, serine and threonine metabolism -2.07 0.00e+0 31/40 (77.5%) GCAT;PGAM1;CBS;...
Glyoxylate and dicarboxylate metabolism -2.09 0.00e+0 23/30 (76.67%) MDH1;MMUT;AGXT;...
Proximal tubule bicarbonate reclamation -2.10 0.00e+0 21/23 (91.3%) CA4;GLUD1;GLUD2;...
DNA replication -2.47 0.00e+0 34/36 (94.44%) POLE;LIG1;RFC1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H